These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28961308)

  • 41. Imaging Findings in Children Presenting with CNS Nelarabine Toxicity.
    Serrallach BL; Schafer ES; Kralik SK; Tran BH; Huisman TAGM; Wright JN; Morgan LA; Desai NK
    AJNR Am J Neuroradiol; 2022 Dec; 43(12):1802-1809. PubMed ID: 36328408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
    Curbo S; Karlsson A
    Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia.
    Pandey RK; DiPippo A; Kadia T; Pemmaraju N; Workeneh BT; Jabbour E; Ravandi F; Jain N
    Leuk Lymphoma; 2020 Nov; 61(11):2775-2777. PubMed ID: 32654562
    [No Abstract]   [Full Text] [Related]  

  • 44. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
    Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
    Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?
    Agrawal AK; Michlitsch J; Golden C; Hastings CA; Raphael R; Feusner JH
    J Clin Oncol; 2021 Feb; 39(6):694. PubMed ID: 33444071
    [No Abstract]   [Full Text] [Related]  

  • 46. Acute methotrexate neurotoxicity revealed by a cerebellar syndrome.
    Zahra K; Bouneb R; Mahjoub M; Zaghouani H; Zaier M; Ben Youssef Y; Khelif A
    Rev Neurol (Paris); 2016 Dec; 172(12):791-793. PubMed ID: 27773447
    [No Abstract]   [Full Text] [Related]  

  • 47. Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia.
    Gollard RP; Selco S
    J Clin Oncol; 2013 Jul; 31(19):e327-31. PubMed ID: 23715575
    [No Abstract]   [Full Text] [Related]  

  • 48. Nelarabine in the treatment of refractory T-cell malignant diseases.
    Kline J; Larson RA
    Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
    Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
    Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
    Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia.
    Ghara N; Saha V
    Lancet Haematol; 2023 Jun; 10(6):e391-e393. PubMed ID: 37167993
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
    Berg SL; Blaney SM; Devidas M; Lampkin TA; Murgo A; Bernstein M; Billett A; Kurtzberg J; Reaman G; Gaynon P; Whitlock J; Krailo M; Harris MB;
    J Clin Oncol; 2005 May; 23(15):3376-82. PubMed ID: 15908649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nelarabine.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia.
    Braish JS; Kugler E; Jabbour E; Woodman K; Ravandi F; Nicholas S; Jain N; Kantarjian H; Sasaki K
    Clin Lymphoma Myeloma Leuk; 2024 Jun; ():. PubMed ID: 39013740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
    Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS
    J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
    Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
    Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
    [No Abstract]   [Full Text] [Related]  

  • 58. Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Fulcher J; Berardi P; Christou G; Villeneuve PJA; Bredeson C; Sabloff M
    Leuk Lymphoma; 2021 Sep; 62(9):2295-2297. PubMed ID: 33749497
    [No Abstract]   [Full Text] [Related]  

  • 59. Update on biology and treatment of T-cell acute lymphoblastic leukaemia.
    Patrick K; Vora A
    Curr Opin Pediatr; 2015 Feb; 27(1):44-9. PubMed ID: 25502893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.